These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 38216938)

  • 1. Recent advances in various adeno-associated viruses (AAVs) as gene therapy agents in hepatocellular carcinoma.
    Hadi M; Qutaiba B Allela O; Jabari M; Jasoor AM; Naderloo O; Yasamineh S; Gholizadeh O; Kalantari L
    Virol J; 2024 Jan; 21(1):17. PubMed ID: 38216938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma.
    Wang YG; Huang PP; Zhang R; Ma BY; Zhou XM; Sun YF
    World J Gastroenterol; 2016 Jan; 22(1):326-37. PubMed ID: 26755879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy.
    Chandler RJ; LaFave MC; Varshney GK; Trivedi NS; Carrillo-Carrasco N; Senac JS; Wu W; Hoffmann V; Elkahloun AG; Burgess SM; Venditti CP
    J Clin Invest; 2015 Feb; 125(2):870-80. PubMed ID: 25607839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma.
    Dhungel B; Jayachandran A; Layton CJ; Steel JC
    Drug Deliv; 2017 Nov; 24(1):289-299. PubMed ID: 28165834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy using adeno-associated virus vectors.
    Daya S; Berns KI
    Clin Microbiol Rev; 2008 Oct; 21(4):583-93. PubMed ID: 18854481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transduction of hepatocellular carcinoma (HCC) using recombinant adeno-associated virus (rAAV): in vitro and in vivo effects of genotoxic agents.
    Peng D; Qian C; Sun Y; Barajas MA; Prieto J
    J Hepatol; 2000 Jun; 32(6):975-85. PubMed ID: 10898318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. scAAVengr, a transcriptome-based pipeline for quantitative ranking of engineered AAVs with single-cell resolution.
    Öztürk BE; Johnson ME; Kleyman M; Turunç S; He J; Jabalameli S; Xi Z; Visel M; Dufour VL; Iwabe S; Pompeo Marinho LFL; Aguirre GD; Sahel JA; Schaffer DV; Pfenning AR; Flannery JG; Beltran WA; Stauffer WR; Byrne LC
    Elife; 2021 Oct; 10():. PubMed ID: 34664552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AAV Infection: Protection from Cancer.
    Srivastava A; Carter BJ
    Hum Gene Ther; 2017 Apr; 28(4):323-327. PubMed ID: 27832705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
    Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
    J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer gene therapy using adeno-associated virus vectors.
    Park K; Kim WJ; Cho YH; Lee YI; Lee H; Jeong S; Cho ES; Chang SI; Moon SK; Kang BS; Kim YJ; Cho SH
    Front Biosci; 2008 Jan; 13():2653-9. PubMed ID: 17981740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The state of the art of adeno-associated virus-based vectors in gene therapy.
    Coura Rdos S; Nardi NB
    Virol J; 2007 Oct; 4():99. PubMed ID: 17939872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AAV vector integration sites in mouse hepatocellular carcinoma.
    Donsante A; Miller DG; Li Y; Vogler C; Brunt EM; Russell DW; Sands MS
    Science; 2007 Jul; 317(5837):477. PubMed ID: 17656716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of adeno-associated virus (AAV) into the genomes of most Thai and Mongolian liver cancer patients does not induce oncogenesis.
    Schäffer AA; Dominguez DA; Chapman LM; Gertz EM; Budhu A; Forgues M; Chaisaingmongkol J; Rabibhadana S; Pupacdi B; Wu X; Bayarsaikhan E; Harris CC; Ruchirawat M; Ruppin E; Wang XW
    BMC Genomics; 2021 Nov; 22(1):814. PubMed ID: 34763675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the potential for AAV vector genotoxicity in a murine model.
    Li H; Malani N; Hamilton SR; Schlachterman A; Bussadori G; Edmonson SE; Shah R; Arruda VR; Mingozzi F; Wright JF; Bushman FD; High KA
    Blood; 2011 Mar; 117(12):3311-9. PubMed ID: 21106988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration and the risk of liver cancer-Is there a real risk?
    Kasimsetty A; Sabatino DE
    J Viral Hepat; 2024 Apr; 31 Suppl 1():26-34. PubMed ID: 38606944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in delivery vectors for gene therapy in liver cancer.
    Redd Bowman KE; Lu P; Vander Mause ER; Lim CS
    Ther Deliv; 2020 Jan; 11(1):833-850. PubMed ID: 31840560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy.
    Grimm D; Kay MA
    Curr Gene Ther; 2003 Aug; 3(4):281-304. PubMed ID: 12871018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preferential targeting of disseminated liver tumors using a recombinant adeno-associated viral vector.
    Della Peruta M; Badar A; Rosales C; Chokshi S; Kia A; Nathwani D; Galante E; Yan R; Arstad E; Davidoff AM; Williams R; Lythgoe MF; Nathwani AC
    Hum Gene Ther; 2015 Feb; 26(2):94-103. PubMed ID: 25569358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring for liver cancer post-gene therapy-How much and how often?
    P de Jong Y; Jacobson IM
    J Viral Hepat; 2024 Apr; 31 Suppl 1(Suppl 1):35-40. PubMed ID: 38606953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.
    Louis Jeune V; Joergensen JA; Hajjar RJ; Weber T
    Hum Gene Ther Methods; 2013 Apr; 24(2):59-67. PubMed ID: 23442094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.